NCT04925063 is a Phase 2 clinical trial of Metformin in Metastatic Prostate Cancer, sponsored by Sun Yat-sen University.

Who is sponsoring NCT04925063?

NCT04925063 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT04925063?

Interventions in NCT04925063: Metformin.

What condition does NCT04925063 study?

NCT04925063 studies Metastatic Prostate Cancer.

Is NCT04925063 still recruiting?

NCT04925063 is currently not yet recruiting. Last updated 14 June 2021.

Last reviewed 2021-06-14 · How we verify

NCT04925063

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Metformin in Patients With Newly Diagnosed mHSPC

Not yet recruiting Phase 2 Last updated 14 June 2021

What this trial tests

Phase 2 trial testing Metformin in Metastatic Prostate Cancer in 266 participants. Not yet recruiting.

Timeline

16 June 2021

Primary endpoint
30 April 2027

31 August 2027

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	266
Start date	16 June 2021
Primary completion	30 April 2027
Estimated completion	31 August 2027
Sites	1 location across China

Drugs / interventions tested

Metformin (metformin) — full drug profile →

Conditions studied

Metastatic Prostate Cancer — all drugs for Metastatic Prostate Cancer →

Sponsor

Sun Yat-sen University

Who can join

18 and older, male only, with Metastatic Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the effect of the addition of metformin to abiraterone on survival in patients with newly diagnosed metastatic hormone-sensitive prostate cancer. The half the patients will receive metformin in combination with androgen deprivation therapy (ADT) and abiraterone, and the other half will receive ADT and abiraterone only.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions.
Fu L, Jin W, Zhang J, Zhu L, et al · · 2022 · cited 47× · PMID 35256933 · DOI 10.1016/j.apsb.2021.09.006
Metformin: A Dual-Role Player in Cancer Treatment and Prevention.
Galal MA, Al-Rimawi M, Hajeer A, Dahman H, et al · · 2024 · cited 44× · PMID 38612893 · DOI 10.3390/ijms25074083
Targeting Mitochondrial OXPHOS and Their Regulatory Signals in Prostate Cancers.
Chen CL, Lin CY, Kung HJ. · · 2021 · cited 39× · PMID 34948229 · DOI 10.3390/ijms222413435

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting

Other recruiting trials for Metastatic Prostate Cancer

Currently open trials in the same condition.

NCT07145177 — 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer · Phase 1 · recruiting
NCT07290270 — Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN) · recruiting
NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
NCT07209176 — Physician- and Patient-based Barriers to NGS Testing · NA · recruiting
NCT07181161 — Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer · Phase 1, PHASE2 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04925063 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 14 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04925063.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing